Research, tested a panel of scFvs in silico and in vitro in order to determine the degree of specificity to EGFRvIII and cross specificity with wild-type EGFR. They then further tested the lead humanized CAR for safety in mouse models grafted with normal EGFR-expressing human skin.

The investigators also tested the lead humanized CAR for efficacy in three mouse models implanted with human glioblastoma cell lines, says Maus. The CAR T cells controlled or shrank most tumors whether the tumors were intracranial or under the skin. Administered intravenously, the engineered T cells controlled the tumor most effectively when given in combination with temozolomide.

The study is the basis for a new phase I trial, based at Penn and the University of California, San Francisco, that is currently enrolling up to 12 adults with EGFRVIII-positive glioblastoma who have either relapsed after standard therapy or have residual disease following surgery, says Maus. Investigators will remove patients’ own T cells and reprogram them to target EGFRVIII-expressing tumor cells when they are returned to the patients via intravenous injection.

Improving PET Evaluation of Brain Tumors

To survive and proliferate, cancer cells undergo metabolic reprogramming and avidly consume various nutrients, including glucose. 18F-fluorodeoxyglucose (18F-FDG), a glucose analog, is usually the radiolabeled tracer of choice when PET is used to evaluate tumors.

However, not all cancers can be clearly imaged with 18F-FDG-based PET, including glioma, an aggressive form of brain cancer. “It’s difficult to distinguish these tumors, because normal brain cells also metabolize high amounts of glucose,” says Sriram Venneti, MD, PhD, a neuropathologist at the University of Michigan in Ann Arbor and first author of a recent study showing that 18F-fluoroglutamine (18F-FGln), an analog of the amino acid glutamine, is a more specific PET tracer for glioma in mice and humans (Sci Transl Med 2015;7:274ra17).

Highly dependent on glutamine, many cancers synthesize it and import still more from extracellular sources. Hypothesizing that “this addiction could be leveraged to noninvasively assess brain tumors,” Venneti collaborated with colleagues at Memorial Sloan Kettering Cancer Center in New York, NY, and the University of Pennsylvania in Philadelphia to develop 18F-FGln.

In several mouse models of glioma, the researchers found that the uptake of 18F-FGln was significantly higher in tumors than in normal brain tissue. In contrast, the uptake of 18F-FDG was equivalent in tumors and normal tissue. With 18F-FGln, tumor-to-background ratios ranged from 4:1 to 6:1, enabling clear tumor delineation; this ratio was approximately 1:1 with 18F-FDG. The researchers verified that the marked 18F-FGln uptake seen in glioma was not influenced by neuroinflammation or a leaky blood-brain barrier.

Venneti’s team then compared 18F-FGln with MRI in imaging glioma-bearing mice before and after treatment with chemotherapy and radiation. 18F-FGln’s uptake dropped significantly after treatment; however, MRI scans before and after were not appreciably different.

Ralph DeBerardinis, MD, PhD, an associate professor at the University of Texas Southwestern Medical Center in Dallas, is encouraged that 18F-FGln-based PET “reports therapy-induced metabolic changes in these mice long before tumor size changes” on MRI. “This is exactly what glucose-based PET monitors in many other cancers, but has been difficult to capture in gliomas,” he says.

Additionally, 18F-FGln-based PET may help separate pseudoprogression—a treatment-related MRI pattern mimicking disease progression—from actual tumor recurrence, “a difficult distinction to make in the clinic,” Venneti adds.

Testing the agent in patients who had undergone surgery, Venneti and his colleagues saw avid uptake and retention of 18F-FGln in three patients whose gliomas recurred, but not in three others whose tumors had not. Where 18F-FDG outlined only part of the tumor in one patient, 18F-FGln
clearly delineated the same tumor in its entirety—which is important, Ven-
neti notes, because gliomas are highly invasive.

“Hopefully, this agent performs as well outside the brain,” says Peter Choyke, MD, director of the NCI’s molecular imaging program in Bethesda, MD. “It will be particularly interesting to see whether glutamine uptake in tumors leads to clinical responses for a new generation of drugs targeting glutamine transport and metabolism.”

Parsing Pancreatic Cancer

In a recently reported study, whole-
genome sequencing of 100 pancreatic
ductal adenocarcinomas identified four tumor subtypes based on DNA structural variation, distinctions that may help guide treatment choices in the future (Nature 2015;518:495–501).

Current treatments for pancreatic cancer are often toxic and work in only a subset of patients. Matching treat-
ments to patients who might benefit remains an urgent need, says study co-director Andrew V. Biankin, MD, PhD, of the University of Glasgow in Scotland and the Garvan Institute of Medical Research in Sydney, Australia.

In collaboration with the Interna-
tional Cancer Genome Consortium, the researchers performed deep whole-genome sequencing and copy number–variation analysis on tissue from early-stage tumors. The study extended previous exome sequenc-
ing analysis, and found both known and new genes mutated at moderate or high frequency and many genes mutated at low frequency. More importantly, Biankin says, the whole-
genome approach revealed structural aberrations that contribute signifi-
cantly to the overall mutational bur-
den in tumors, including the deletion, amplification, and rearrangement of large pieces of DNA.

Analysis of patterns of structural variation identified four distinct tumor types: stable, locally rearranged, scattered, and unstable. The stable group had the fewest DNA rearrange-
ments, while the locally rearranged and scattered groups showed an inter-
mediate level, clustered on one or two chromosomes or distributed among multiple chromosomes, respectively. The unstable group, accounting for 14% of tumors, showed the most frequent structural changes, with more than 200 per genome. Most of the tumors in this group had muta-
tions in key maintenance and repair enzymes—BRCA1, BRCA2, or PALB2—or displayed a mutational signature of DNA repair deficiency.

Because DNA repair deficiency may impart sensitvity to DNA-damaging drugs, the researchers looked at out-
comes for patients who had received platinum-based chemotherapy. Of eight patients in the study treated with platinum agents, four of the five with unstable genomes and/or a mutational signature of DNA repair deficiency responded to treatment. Three patients with other tumor sub-
types did not respond.

“These are small numbers, so we have to be cautious, but this is a potential biomarker for us to take forward into clinical trials and start to test whether we can better select patients for specific treatment,” Biankin says.

That possibility excites Steven D. Leach, MD, of Memorial Sloan Kettering Cancer Center in New York, NY, who was not involved in the work. “For the first time in pancreatic cancer, we see genomic data that may have predictive value in terms of what therapies are likely to work for subsets of patients,” he says.
CANCER DISCOVERY

Improving PET Evaluation of Brain Tumors


Updated version	Access the most recent version of this article at: doi:10.1158/2159-8290.CD-NB2015-038